ACEA Biosciences
Klaus Kuhn has extensive experience in the life sciences industry, with a focus on field application support for various companies. Klaus started their career in 2002 as a Staff Scientist at The Scripps Research Institute, where they worked until 2006. In 2007, they joined Life Technologies as a Field Application Scientist, providing pre- and post-sale support for benchtop devices. Klaus was later promoted to Senior Field Application Scientist, expanding their responsibilities to include product demos, seminars, customer training, product shows, and product development activities. Klaus then transitioned to ACEA Biosciences in 2014, where they currently hold the position of Senior Field Application Scientist. In this role, they organize pre- and post-sale support activities for ACEA's flow cytometry products, including remote technical and scientific support, as well as on-site demos.
Klaus Kuhn earned their PhD in Molecular Immunology from the University of Erlangen-Nurnberg, where they attended from 1987 to 1992. In addition, they obtained a certification in Six Sigma Green Belt from the Life Technologies in-house certification program, although the specific month and year of attainment are not provided.
This person is not in any offices
ACEA Biosciences
ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China.The Life TechnologyBusiness Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology.The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005.ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.